QC
DMAC icon

Quadrature Capital’s DiaMedica Therapeutics DMAC Stock Holding History

Quadrature Capital’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,039
Closed -$149K – 1694
2026
Q1 		$149K Sell
22,039
-1,533
-7% -$12.1K ﹤0.01% 1173
2025
Q4 		$188K Buy
+23,572
New +$176K ﹤0.01% 989

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Quadrature Capital's DMAC Position: Q2 2026 in Review

Quadrature Capital sold out of DiaMedica Therapeutics (DMAC) in Q2 2026, closing a stake of 22,039 shares — an estimated $149K sold.

Quadrature Capital first reported a position in DMAC in Q4 2025 and held it in 2 quarters. The position peaked at $188K in Q4 2025. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Quadrature Capital reported no remaining DiaMedica Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrature Capital sold 22,039 DiaMedica Therapeutics shares in Q2 2026, an estimated $149K.
  • Quadrature Capital first reported a position in DiaMedica Therapeutics in Q4 2025 and held it in 2 quarters.
  • Quadrature Capital's DiaMedica Therapeutics position peaked at $188K in Q4 2025.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.